Public Health Service, Murcia   Report issue

Government Phase 1
Founded: Spain

Organization Overview

First Clinical Trial
2014
NCT02286011
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 1)

Motor Neuron Disease (Phase 1)

Osteonecrosis (Phase 1)

Osteoporosis (Phase 1)

Retinitis (Phase 1)

Retinitis Pigmentosa (Phase 1)

Sclerosis (Phase 1)

Spinal Fractures (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 4